The intent of management is to reduce the formation of new inflammatory lesions, sinus tracts, and scarring; to treat existing lesions and reduce associated symptoms (e.g., pain, infection); and to improve associated comorbidities.
Treatment depends on disease severity and impact on quality of life. The Hurley classification scale approximates disease severity at presentation and can be used to stratify patients into groups who receive increasing intensity of treatment. It is useful to guide treatment choice.[4]Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus. In: Roenigk RH, Roenigk HH Jr, eds. Dermatologic surgery: principles and practice. New York, NY: Marcel Dekker; 1989:729-739.[36]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019 Jul;81(1):76-90.
https://www.doi.org/10.1016/j.jaad.2019.02.067
http://www.ncbi.nlm.nih.gov/pubmed/30872156?tool=bestpractice.com
[41]Martorell A, García FJ, Jiménez-Gallo D, et al. Update on hidradenitis suppurativa (part II): treatment. Actas Dermosifiliogr. 2015;106:716-724.
http://www.actasdermo.org/en/update-on-hidradenitis-suppurative-part/articulo/S1578219015002449
http://www.ncbi.nlm.nih.gov/pubmed/26277040?tool=bestpractice.com
Treatment is often multidisciplinary.[1]Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158-164.
http://www.ncbi.nlm.nih.gov/pubmed/22236226?tool=bestpractice.com
[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
Early referral to a dermatologist is recommended if patients don’t respond to one to two courses of long-term (3 months) antibiotics in the community. Medical therapy includes use of topical and oral antibiotics, retinoids, and in moderate to severe disease, biological agents. Discussion of surgical options should also be considered.
Acute symptoms
In the acute setting, oral antibiotics should be initiated. Guidelines recommend a 12-week course of a tetracycline antibiotic.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
In severe HS presenting with a disease flare, rescue therapy in the form of a 6-week course of intravenous ertapenem, followed by a 6-week course of consolidation treatment with moxifloxacin plus metronidazole plus rifampicin, may be considered.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
[45]Chahine AA, Nahhas AF, Braunberger TL, et al. Ertapenem rescue therapy in hidradenitis suppurativa. JAAD Case Rep. 2018 Jun;4(5):482-3.
http://www.ncbi.nlm.nih.gov/pubmed/29984290?tool=bestpractice.com
[46]Join-Lambert O, Coignard-Biehler H, Jais JP, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016 Feb;71(2):513-20.
https://www.doi.org/10.1093/jac/dkv361
http://www.ncbi.nlm.nih.gov/pubmed/26565016?tool=bestpractice.com
If the patient is well, intralesional corticosteroids may provide relief from pain and inflammation, in combination with oral antibiotics if required.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
[47]Riis PT, Boer J, Prens EP, et al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol. 2016 Dec;75(6):1151-5.
http://www.ncbi.nlm.nih.gov/pubmed/27692735?tool=bestpractice.com
If the patient is unwell or disease does not improve with antibiotics and/or intralesional corticosteroids, incision and drainage may be considered.[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
Incision and drainage is a supplemental measure; it should not be considered as the sole treatment because recurrence is very common.
Ongoing management: mild disease (Hurley Stage I)
Stage I is defined as the presence of localised disease with inflammatory papules, pustules, nodules, and abscesses but without sinus tracts or scarring.[4]Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus. In: Roenigk RH, Roenigk HH Jr, eds. Dermatologic surgery: principles and practice. New York, NY: Marcel Dekker; 1989:729-739.[Figure caption and citation for the preceding image starts]: Hidradenitis suppurativa stage I: discrete inflamed nodules and papules with intervening normal skin and lack of scarringFrom R.A. Lee, MD, PhD [Citation ends].
Topical therapies
It is recommended that all patients use an antimicrobial wash, but there is no strong evidence for specific agents; use of chlorhexidine, benzoyl peroxide, and zinc pyrithione is supported by expert opinion. Concomitant use of an antimicrobial wash may be associated with lower rates of antibiotic resistance in HS lesions.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[48]Leiphart P, Ma H, Naik HB, et al. The effect of antimicrobial washes on antibacterial resistance in hidradenitis suppurativa lesions. J Am Acad Dermatol. 2019 Mar;80(3):821-2.
https://www.doi.org/10.1016/j.jaad.2018.10.063
http://www.ncbi.nlm.nih.gov/pubmed/30403961?tool=bestpractice.com
Topical antibiotics are useful treatments in mild HS.[41]Martorell A, García FJ, Jiménez-Gallo D, et al. Update on hidradenitis suppurativa (part II): treatment. Actas Dermosifiliogr. 2015;106:716-724.
http://www.actasdermo.org/en/update-on-hidradenitis-suppurative-part/articulo/S1578219015002449
http://www.ncbi.nlm.nih.gov/pubmed/26277040?tool=bestpractice.com
Topical clindamycin has been shown to be effective in a clinical trial setting.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[49]Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971-4.
http://www.ncbi.nlm.nih.gov/pubmed/9843011?tool=bestpractice.com
Topical metronidazole is another option. Topical therapy should be continued for a minimum of 8 weeks before evaluation of efficacy.
Antibiotic therapy
Systemic antibiotics are widely used and recommended in multiple HS treatment guidelines.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
Oral tetracyclines are recommended first-line for mild disease. They can attenuate neutrophil activity and reduce pain and inflammation. A 12-week treatment course is recommended before evaluation of efficacy.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
Analgesia
The degree of pain usually correlates with the degree of inflammation. Thus, treatments directed at inflammation are often effective at alleviating pain. Non-steroidal anti-inflammatory drugs should be used as required before other pain medications such as paracetamol.
Lifestyle modifications
A high proportion of patients with hidradentitis suppurativa are active smokers or have a history of smoking, and are obese. Obesity is an independent risk factor for development of the disease and contributes to HS disease severity.[21]Tzellos T, Zouboulis CC, Gulliver W, et al. Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies. Br J Dermatol. 2015 Nov;173(5):1142-55.
http://www.ncbi.nlm.nih.gov/pubmed/26153913?tool=bestpractice.com
[24]Jørgensen AR, Yao Y, Ghazanfar MN, et al. Burden, predictors and temporal relationships of comorbidities in patients with hidradenitis suppurativa: a hospital-based cohort study. J Eur Acad Dermatol Venereol.
http://www.ncbi.nlm.nih.gov/pubmed/31442338?tool=bestpractice.com
All patients should be advised to stop smoking, to lose weight if obese, and to be evaluated for cardiovascular disease.[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
[50]Kromann CB, Ibler KS, Kristiansen VB, et al. The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014 Sep;94(5):553-7.
https://www.doi.org/10.2340/00015555-1800
http://www.ncbi.nlm.nih.gov/pubmed/24577555?tool=bestpractice.com
Ongoing management: moderate disease (Hurley Stage II)
Stage II is defined as the presence of inflammatory papules and nodules, ≥1 recurring, widely separated abscesses with sinus tracts and scarring.[4]Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus. In: Roenigk RH, Roenigk HH Jr, eds. Dermatologic surgery: principles and practice. New York, NY: Marcel Dekker; 1989:729-739.[41]Martorell A, García FJ, Jiménez-Gallo D, et al. Update on hidradenitis suppurativa (part II): treatment. Actas Dermosifiliogr. 2015;106:716-724.
http://www.actasdermo.org/en/update-on-hidradenitis-suppurative-part/articulo/S1578219015002449
http://www.ncbi.nlm.nih.gov/pubmed/26277040?tool=bestpractice.com
[Figure caption and citation for the preceding image starts]: Hidradenitis suppurativa stage II: inflamed nodules and scars with areas of intervening normal skinFrom R.A. Lee, MD, PhD [Citation ends].
Antibiotic therapy
Tetracyclines are recommended for 12 weeks.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
Clindamycin plus rifampicin is an effective combination and should be continued for 10 to 12 weeks.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
However, patients often relapse within 4 to 5 months of stopping therapy.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
[51]Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients.
Dermatology. 2009;219:148-54.
http://www.ncbi.nlm.nih.gov/pubmed/19590173?tool=bestpractice.com
Diarrhoea may reduce tolerability of clindamycin plus rifampicin in some patients.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
Patients who are aged ≥50 years or ever-smokers are less likely to tolerate this combination.[36]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019 Jul;81(1):76-90.
https://www.doi.org/10.1016/j.jaad.2019.02.067
http://www.ncbi.nlm.nih.gov/pubmed/30872156?tool=bestpractice.com
[52]Schneller-Pavelescu L, Vergara-de Caso E, Martorell A, et al. Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes. J Am Acad Dermatol. 2019 May;80(5):1455-7.
https://www.doi.org/10.1016/j.jaad.2018.12.043
http://www.ncbi.nlm.nih.gov/pubmed/30630028?tool=bestpractice.com
[53]Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):619-44.
http://www.ncbi.nlm.nih.gov/pubmed/25640693?tool=bestpractice.com
Rifampicin induces the cytochrome P450 system; check for potential drug interactions with existing medication including the oral contraceptive pill. Clindamycin plus rifampicin may also select for rifampicin-resistant strains of Mycobacterium tuberculosis; tuberculosis screening or avoiding this regimen may be indicated in high-risk populations.[54]Mendes-Bastos P, Macedo R, Duarte R. Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis? Br J Dermatol. 2017 Oct;177(4):e150-e151.
http://www.ncbi.nlm.nih.gov/pubmed/28718933?tool=bestpractice.com
Triple antibiotic therapy with moxifloxacin plus metronidazole plus rifampicin is a second-line option for moderate HS.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
Dapsone
Dapsone is reserved for patients with moderate disease who have failed multiple courses of combination antibiotics.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
Evidence is limited; in one published case series, 25% patients experienced clinically significant improvement but with rapid disease recurrence upon cessation.[55]Yazdanyar S, Boer J, Ingvarsson G, et al. Dapsone therapy for hidradenitis suppurativa: a series of 24 patients. Dermatology. 2011;222(4):342-6.
http://www.ncbi.nlm.nih.gov/pubmed/21757878?tool=bestpractice.com
Anti-androgens
North American guidelines suggest that hormonal agents, including spironolactone, may be considered in women with clear premenstrual flares (while recognising that recommendations regarding hormonal therapies are based on limited evidence).[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
Use of spironolactone should be limited to women who are practising adequate birth control.
UK guidelines conclude that there is insufficient evidence to recommend anti-androgens for the treatment of HS.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[56]Nikolakis G, Kyrgidis A, Zouboulis CC. Is there a role for antiandrogen therapy for hidradenitis suppurativa? A systematic review of published data. Am J Clin Dermatol. 2019 Aug;20(4):503-13.
http://www.ncbi.nlm.nih.gov/pubmed/31073704?tool=bestpractice.com
Oral retinoids
Patients with concomitant acne vulgaris may consider using oral isotretinoin.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[57]Boer J, van Gemert MJ. Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol. 1999;40:73-6.
http://www.ncbi.nlm.nih.gov/pubmed/9922015?tool=bestpractice.com
Oral isotretinoin should be continued for at least 6 months.
Acitretin has demonstrated moderate efficacy in HS.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[58]Boer J, Nazary M. Long-term results of acitretin therapy for hidradenitis suppurativa.
Br J Dermatol. 2010;164:170-5.
http://www.ncbi.nlm.nih.gov/pubmed/20874789?tool=bestpractice.com
Treatment duration in excess of 6 months has been reported.[59]Blok JL, van Hattem S, Jonkman MF, et al. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243-52.
http://www.ncbi.nlm.nih.gov/pubmed/23106519?tool=bestpractice.com
These medications are teratogenic and should be avoided in women of child-bearing potential.
Surgical management
Wide excision with wide and deep margins is the standard of care for surgical therapy. Because of the size of the excision and its corresponding repair, and the availability of specific lasers, referral to plastic surgery and/or a dermatological surgeon is advisable.[60]van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol. 2010;63:475-480.
http://www.ncbi.nlm.nih.gov/pubmed/20708472?tool=bestpractice.com
[61]Tierney E, Mahmoud BH, Hexsel C, et al. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2009;35:1188-1198.
http://www.ncbi.nlm.nih.gov/pubmed/19438670?tool=bestpractice.com
[62]Mahmoud BH, Tierney E, Hexsel CL, et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol. 2010;62:637-645.
http://www.ncbi.nlm.nih.gov/pubmed/20227579?tool=bestpractice.com
[63]Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010;36:208-213.
http://www.ncbi.nlm.nih.gov/pubmed/20039918?tool=bestpractice.com
Local excision is possible for smaller, quiescent lesions where the clinical margins can be clearly defined.
Adjunctive therapies and self-management
Topical therapies, analgesia, and lifestyle modifications may be considered (as for patients with mild disease).
Ongoing management: severe disease (Hurley Stage III)
Stage III disease is defined as multiple abscesses and interconnected sinus tracts and scars.[4]Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus. In: Roenigk RH, Roenigk HH Jr, eds. Dermatologic surgery: principles and practice. New York, NY: Marcel Dekker; 1989:729-739.[Figure caption and citation for the preceding image starts]: Hidradenitis suppurativa stage III: interconnected scars, cysts, comedones, and inflamed nodulesFrom R.A. Lee, MD, PhD [Citation ends].
The strategies for stage III disease overlap with those for stage I and II disease. In practice, patients in this group will have previously used oral tetracyclines, and they may be used again in between other measures to maintain disease control in stage III disease. However, once disease reaches stage III more aggressive treatment is usually required.
Antibiotic therapy
In selected stage III patients with severe HS presenting with a disease flare (usually after failure of a tetracycline [for 12 weeks] or clindamycin plus rifampicin), a 6-week course of intravenous ertapenem, followed by a 6-week course of consolidation treatment with moxifloxacin plus metronidazole plus rifampicin, may be considered.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
[45]Chahine AA, Nahhas AF, Braunberger TL, et al. Ertapenem rescue therapy in hidradenitis suppurativa. JAAD Case Rep. 2018 Jun;4(5):482-3.
http://www.ncbi.nlm.nih.gov/pubmed/29984290?tool=bestpractice.com
[46]Join-Lambert O, Coignard-Biehler H, Jais JP, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016 Feb;71(2):513-20.
https://www.doi.org/10.1093/jac/dkv361
http://www.ncbi.nlm.nih.gov/pubmed/26565016?tool=bestpractice.com
Biological agents
Adalimumab has demonstrated efficacy in phase 3 trials of HS.[64]Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375:422-34.
http://www.nejm.org/doi/full/10.1056/NEJMoa1504370#t=article
http://www.ncbi.nlm.nih.gov/pubmed/27518661?tool=bestpractice.com
It is the only approved biologic for HS, and is therefore considered the first-choice biological agent in moderate/severe HS refractory to conventional treatments.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
Infliximab may be considered as a second-line biological agent, and is used off-label for HS.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
[44]Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19-31.
https://www.doi.org/10.1111/jdv.15233
http://www.ncbi.nlm.nih.gov/pubmed/30176066?tool=bestpractice.com
Other biological agents may be considered if adalimumab or infliximab fail or are contraindicated, but their use is off-label and should be under specialist guidance.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
Therapy with biologics is continued for at least 12 weeks and the efficacy of treatment assessed at this time.
Surgical management
Wide excision with wide and deep margins is the standard of care for surgical therapy. Because of the size of the excision and its corresponding repair, and the availability of specific lasers, referral to plastic surgery and/or a dermatological surgeon is advisable.[60]van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol. 2010;63:475-480.
http://www.ncbi.nlm.nih.gov/pubmed/20708472?tool=bestpractice.com
[61]Tierney E, Mahmoud BH, Hexsel C, et al. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2009;35:1188-1198.
http://www.ncbi.nlm.nih.gov/pubmed/19438670?tool=bestpractice.com
[62]Mahmoud BH, Tierney E, Hexsel CL, et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol. 2010;62:637-645.
http://www.ncbi.nlm.nih.gov/pubmed/20227579?tool=bestpractice.com
[63]Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010;36:208-213.
http://www.ncbi.nlm.nih.gov/pubmed/20039918?tool=bestpractice.com
Local excision is possible for smaller, quiescent lesions where the clinical margins can be clearly defined.
Adjunctive therapies and self-management
Topical therapies, analgesia, and lifestyle modifications may be considered (as for patients with mild disease).
Women with clear premenstrual flares should consider using anti-androgen medications such as spironolactone.[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com
Oral retinoids may be considered in patients with concomitant acne vulgaris.[42]Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-17.
https://www.doi.org/10.1111/bjd.17537
http://www.ncbi.nlm.nih.gov/pubmed/30552762?tool=bestpractice.com
[43]Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019 Jul;81(1):91-101.
https://www.doi.org/10.1016/j.jaad.2019.02.068
http://www.ncbi.nlm.nih.gov/pubmed/30872149?tool=bestpractice.com